Potency of Peripheral Blood- and Umbilical Cord Blood-derived Dendritic Cells and Their Secretomes as Vaccines for Cancer
Abstract
Dendritic cell (DC) vaccines, as immunotherapy agents, can gather up and transport cancer-related antigens to T lymphocytes, activating anti-tumor effector responses. After being activated by DC, cytotoxic T lymphocyte cells (CTL) will secrete the cytolytic granzyme B that can effectively induce rapid apoptosis of target cells. On the other hand, DC also secrete several cytokines and a large number of exosomes, which together operate as a whole antigen-presenting entity. The efficacy of the vaccine’s treatment may be affected by the sources used for DC vaccines. Umbilical cord blood (UCB) from healthy donors can be employed when autologous cancer patient’s peripheral blood (PB) cannot be used as a source for isolating DC due to genetic abnormalities. Comparing UCB to other sources, there is a painless method of collecting sources as opposed to PB, which necessitates a venipuncture or leukapheresis procedure to isolate the blood. Many studies related to the use of PB-DC have been carried out, but research on potential comparisons between PB-DC and UCB-DC is still very limited. In this review, the potential of PB- and UCB-derived DC and their secretomes for cancer will be discussed.
Keywords: dendritic cells, vaccines, umbilical cord blood, peripheral blood
Full Text:
PDFReferences
Al Azhar MA, Nadliroh S, Prameswari K, Handoko, Tobing DL, Herawati C. Profile of PD-1 and PD-L1 mRNA expression in peripheral blood of nasopharyngeal carcinoma. Mol Cell Biomed Sci. 2020; 4(3): 121-7, CrossRef.
Nilsson JS, Abolhalaj M, Lundberg K, Lindstedt M, Greiff L. Dendritic cell subpopulations in nasopharyngeal cancer. Oncol Lett. 2019; 17(2): 2557-61, CrossRef.
Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019; 10(1): 5408, CrossRef.
Sabado RL, Miller E, Spadaccia M, Vengco I, Hasan F, Bhardwaj N. Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. J Vis Exp. 2013; (78): 50085, CrossRef.
Szaryńska M, Preis K, Zabul P, Kmieć Z. Diversity of dendritic cells generated from umbilical cord or adult peripheral blood precursors. Cent Eur J Immunol. 2018; 43(3): 306-13, CrossRef.
Kumar J, Kale V, Limaye L. Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy. Stem Cell Res Ther. 2015; 6: 184, CrossRef.
Nikfarjam S, Rezaie J, Kashanchi F, Jafari R. Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res. 2020; 39(1): 258, CrossRef.
Hood JL. The association of exosomes with lymph nodes. Semin Cell Dev Biol. 2017; 67: 29-38, CrossRef.
Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023; 164: 114954, CrossRef.
Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: Looking to the future. Oncoimmunology. 2013; 2(3): e23403, CrossRef.
Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: Past, present, and future. Adv Cancer Res. 2013; 119: 421-75, CrossRef.
Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Cancer vaccines: The next immunotherapy frontier. Nat Cancer. 2022; 3(8): 911-26, CrossRef.
He JQ, Sun L, He J, Zhu C, Li P, Lei J, et al. The pathogenesis and therapeutics of nasopharyngeal carcinoma. Health Sci J. 2019; 13(2): 642, article.
Tsang CM, Lo KW, Nicholls JM, Huang SCM, Tsao SW. Pathogenesis of nasopharyngeal carcinoma. In: Lee AWM, Lung ML, Ng WT, editors. Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. London: Academic Press; 2019. p.45-64, article.
Velayutham P, Davis P, Savery N, Vaigundavasan R. A common symptom with an uncommon diagnosis. Egyptian J Otolaryngol. 2021; 37: 95, CrossRef.
Mydin RBSMN, Okekpa SI. Molecular pathways for nasopharyngeal carcinoma focused on acetyldehide, nitrosamines, and nicotine exposures. Malays J Med Health Sci. 2019; 15(SP2): 64-70, article.
Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020; 13(1): 107, CrossRef.
Vasaturo A, Di Blasio S, Peeters DG, de Koning CC, de Vries JM, Figdor CG, et al. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: A game of stop and go. Front Immunol. 2013; 4: 417, CrossRef.
Sulistya AB, Haifa R, Facicilia G, Marbun KT, Kirana MN, Dewi YA, et al. Dendritic cell as potential immunotherapy for nasopharyngeal cancer: A review. Indones Biomed J. 2023; 15(5): 269-77, CrossRef.
Cozzi S, Najafi M, Gomar M, Ciammella P, Iotti C, Iaccarino C, et al. Delayed effect of dendritic cells vaccination on survival in glioblastoma: A systematic review and meta-analysis. Curr Oncol. 2022; 29(2): 881-91, CrossRef.
Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: An evolving paradigm. Nat Rev Clin Oncol. 2021; 18(11): 679-95, CrossRef.
Kumar C, Kohli S, Chiliveru S, Bapsy PP, Jain M, Suresh Attili VS, et al. A retrospective analysis comparing APCEDEN® dendritic cell immunotherapy with best supportive care in refractory cancer. Immunotherapy. 2017; 9(11): 889-97, CrossRef.
Varricchi G, Harker J, Borriello F, Marone G, Durham SR, Shamji MH. T follicular helper (Tfh) cells in normal immune responses and in allergic disorders. Allergy. 2016; 71(8): 1086-94, CrossRef.
Olivo Pimentel V, Yaromina A, Marcus D, Dubois LJ, Lambin P. A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry. J Immunol Methods. 2020; 487: 112899, CrossRef.
Chakraborty S, Latheef SK, Munjal A, Tiwari R, Samad HA, Karthik K, et al. Cytotoxic T cells and cancer therapy. J Exp Biol Agric Sci. 2017; 5(4): 412-27, CrossRef.
Facicilia G, Sartika CR, Rostinawati T. In vitro production of dendritic cells as cancer immunotherapy: Highlights on sample source, culture period, differentiation and maturation cytokines. Mol Cell Biomed Sci. 2023; 7(3): 122-32, CrossRef.
Wei XC, Yang DD, Han XR, Zhao YA, Li YC, Zhang LJ, et al. Bioactivity of umbilical cord blood dendritic cells and anti-leukemia effect. Int J Clin Exp Med. 2015; 8(10): 19725-30, article.
Mu Y, Wang WH, Xie JP, Zhang YX, Yang YP, Zhou CH. Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: A randomized phase II study. Onco Targets Ther. 2016; 9: 4617-27, CrossRef.
Cunningham S, Hackstein H. Cord-blood-derived professional antigen-presenting cells: Functions and applications in current and prospective cell therapies. Int J Mol Sci. 2021; 22(11): 5923, CrossRef.
Pitt JM, André F, Amigorena S, Soria JC, Eggermont A, Kroemer G, et al. Dendritic cell-derived exosomes for cancer therapy. J Clin Invest. 2016; 126(4): 1224-32, CrossRef.
Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023; 164: 114954, CrossRef.
Yao Y, Fu C, Zhou L, Mi QS, Jiang A. DC-derived exosomes for cancer immunotherapy. Cancers. 2021; 13(15): 3667, CrossRef.
Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: A role for NKG2D ligands and IL-15Rα. PLoS One. 2009; 4(3): e4942, CrossRef.
Andre F, Escudier B, Angevin E, Tursz T, Zitvogel L. Exosomes for cancer immunotherapy. Ann Oncol. 2004; 15 Suppl 4: iv141-4, CrossRef.
Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008; 19(1): 41-52, CrossRef.
DOI: https://doi.org/10.21705/mcbs.v8i1.358
Copyright (c) 2024 Cell and BioPharmaceutical Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
Cell and BioPharmaceutical Institute
